Araştırma Makalesi
Yıl 2019,
Cilt: 9 Sayı: 3, 220 - 227, 30.09.2019
Öz
Kaynakça
- 1. Drucker AM. Atopic dermatitis: burden of illness, quality of life, and associated complications. Allergy Asthma Proc 2017; 38: 3–8.
- 2. Bieber T. Atopic dermatitis. Ann Dermatol 2010; 22: 125–137.
- 3. Brunner PM, Guttman-Yassky E, Leung DY. The immunology of atopic dermatitis and its reversibility with broad-spectrum and targeted therapies. J Allergy Clin Immunol 2017; 139: 65–76.
- 4. Nutten S. Atopic dermatitis: Global epidemiology and risk factors. Ann Nutr Metab 2015; 66: 8–16.
- 5. Shaw TE, Currie GP, Koudelka CW, Simpson EL. Eczema prevalence in the United States: Data from the 2003 National Survey of Children’s Health. J Invest Dermatol 2011; 131: 67–73.
- 6. Leung DY, Nicklas RA, Li JT, Bernstein IL, Blessing- Moore J, Boguniewicz M va et al. Disease management of atopic dermatitis: an updated practice parameter. Joint Task Force on Practice Parameters. Ann Allergy Asthma Immunol 2004; 93: 1-21.
- 7. Bieber T. Atopic dermatitis. N Engl J Med 2008; 358:1483-1494.
- 8. Brunner PM, Leung DYM, Guttman-Yassky E. Immunologic, microbial, and epithelial interactions in atopic dermatitis. Ann Allergy Asthma Immunol 2018; 120: 34-41.
- 9. Lowes MA, Bowcock AM, Krueger JG. Pathogenesis and therapy of psoriasis. Nature 2007; 445: 66–73.
- 10. Guttman-Yassky E, Lowes MA, Fuentes-Duculan J, et al. Major differences in inflammatory dendritic cells and their products distinguish atopic dermatitis from psoriasis. J Allergy Clin Immunol 2007; 119: 1210–7.
- 11. Org PY, Leung DY. Immune dysregulation in atopic dermatitis. Curr Allergy Asthma Rep 2006; 6: 384–9.
- 12. Khattri S, Shemer A, Rozenblit M, Dhingra N, Czarnowicki T, Finney R va et al. Cyclosporine in patients with atopic dermatitis modulates activated inflammatory pathways and reverses epidermal pathology. J Allergy Clin Immunol 2014; 133: 1626-34.
- 13. Gooderham M, Lynde CW, Papp K, Bourcier M, Guenther L, Gulliver W va et al. Review of systemic treatment options for adult atopic dermatitis. J Cutan Med Surg 2016: 21:31-39.
- 14. Khattri S, Shemer A, Rozenblit M, Dhingra N, Czarnowicki T, Finney R, et al. biomarkers for therapeutic response. J Allergy Clin Immunol 2011; 128: 583-93.
- 15. Tintle S, Shemer A, Suarez-Farinas M, Fujita H, Gilleaudeau P, Sullivan-Whalen M va et al. Reversal of atopic dermatitis with narrow-band UVB phototherapy and biomarkers for therapeutic response. J Allergy Clin Immunol 2011; 128: 583-93.
- 16. Kim HS, Yun JW, Shin TH, Lee SH, Lee BC, Yu KR va et el. Human umbilical cord blood mesenchymal stem cell-derived PGE2 and TGF-beta1 alleviate atopic dermatitis by reducing mast cell degranulation. Stem cells 2015; 33:1254–66.
- 17. Na K, Yoo HS, Zhang YX, Choi MS, Lee K, Yi TG va et el. Bone marrow-derived clonal mesenchymal stem cells inhibit ovalbumin-induced atopic dermatitis. Cell Death Dis 2014; 5: e1345.
- 18. Barry FP, Murphy JM. Mesenchymal stem cells: clinical applications and biological characterization. Int J Biochem Cell Biol 2004; 36: 568–84.
- 19. Duffy MM, Ritter T, Ceredig R, Griffin MD. Mesenchymal stem cell effects on T-cell effector pathways. Stem Cell Res Ther 2011; 2: 34. 20. Saito M. T, Silverio K. G, Casati M. Z, SallumE. A, Nociti F. H. Jr Tooth-derived stem cells: Update and perspectives. World J Stem Cells 2015; 7: 399–407.
- 21. Yildirim S, Zibandeh N, Genc D, Ozcan EM, Goker K, Akkoc T. The Comparison of the Immunologic Properties of Stem Cells Isolated from Human Exfoliated Deciduous Teeth, Dental Pulp, and Dental Follicles. Stem Cells Int 2016; 4682875: 105-106.
- 22. Krampera M, Cosmi L, Angeli R, Pasini A, Liotta F, Andreini A va et al. Role for interferon-gamma in the immunomodulatory activity of human bone marrow mesenchymal stem cells. Stem Cells 2006; 24: 386–398. 23. Ryan JM, Barry F, Murphy JM, Mahon BP. Interferon-gamma does not break, but promotes the immunosuppressive capacity of adult human mesenchymal stem cells. Clin Exp Immunol 2007; 149: 353–63.
- 24. DelaRosa O, Lombardo E, Beraza A, Mancheno-Corvo P, Ramirez C, Menta R va et al. Requirement of IFN-gamma-mediated indoleamine 2,3-dioxygenase expression in the modulation of lymphocyte proliferation by human adipose-derived stem cells. Tissue Eng Part A 2009; 15: 2795–2806.
- 25. Fu Q, Chow Y, Sun S, Zeng Q, Li H, Shi J, et al. Mesenchymal stem cells derived from human induced pluripotent cells modulate T- cell phenotypes in allergic Rhinitis. Allergy 2012; 67: 1215-22.
- 26. Fuss IJ, Kanof M, Smith P, Zola H. Isolation of whole mononuclear cells from peripheral blood and cord blood. Curr Protoc Immunol 2009; Chapter 7:Unit7.1.
- 27. Quah B, Parish C. The Use of Carboxyfluorescein Diacetate Succinimidyl Ester (CFSE) to Monitor Lymphocyte Proliferation. J Vis Exp 2010; 4: 2259.
- 28. Massimiliano D’Erme A, Romanelli M, Chiricozzi A. Spotlight on dupilumab in the treatment of atopic dermatitis: design, development, and potential place in therapy. Drug Des Devel Ther 2017; 11: 1473–80.
- 29. Iyer SS , Rojas M. Anti-inflammatory effects of mesenchymal stem cells: novel concept for future therapies. Expert Opin Biol Ther. 2008; 8: 569-81.
- 30. Lee YS, Sah SK, Lee JH, Seo KW, Kang KS, Kim TY. Human umbilical cord blood-derived mesenchymal stem cells ameliorate psoriasis-like skin inflammation in mice. Biochem Biophys Rep 2016; 9: 281-8. 31. TW, Lim JH, Chung CJ, Kang TJ, Kim TY, Kim YS, et al. Immune Tolerance of Human Dental Pulp-Derived Mesenchymal Stem Cells Mediated by CD4+CD25+FoxP3+ Regulatory T-Cells and Induced by TGF-β1 and IL-10. Yonsei Med J 2017; 58: 1031–39.
- 32. Keyser KA, Beagles KE, Kiem HP. Comparison of mesenchymal stem cells from different tissues to suppress T-cell activation. Cell Transplant 2007; 16: 555-62.
Effect of Dental Follicle Mesenchymal Stem Cell on Th1 and Th2 Derived Naive T Cells in Atopic Dermatitis Patients
Öz
Objective: The purpose of our study is to investigate the immunomodulatory effects of Dental Follicle Mesenchymal Stem Cells (DF-MSCs) on lymphocytes isolated from peripheral blood of AD patients, a Th2 disease and psoriasis, a Th1 / Th17 disease and compare them with healthy individuals in vitro.
Methods: Patients with the AD (n = 9) and psoriasis (n = 6) who are followed up in Marmara University Pediatric Allergy and Immunology and Dermatology outpatient clinics and healthy subjects (n = 6) were included. Peripheral Blood Mononuclear Cells (PBMCs) were isolated from 20 ml of venous blood of all participants. Cells were cultured for 72 hours in the absence and presence of DF-MSCs with anti-CD3/anti-CD28 stimulation or without stimulation. At the end of this period, CD4+ and CD8+ T lymphocyte proliferation and cytokine levels from the culture supernatants were analyzed by flow cytometry.
Results: In the presence of DF-MSCs, proliferation ratio was suppressed in both CD4+ and CD8+ cells in AD and psoriasis patients (p<0,05). IFN-γ levels significantly increased in AD patients in the presence of DF-MSCs (p<0,05) whereas decreased significantly in psoriasis patients in the presence of DF-MSCs (p<0,05). IL-4 levels significantly decreased in AD patients in the presence of DF-MSCs (p<0,05) but remained unchanged in psoriasis patients (p>0,05). IL-10 increased significantly in both groups in the presence of DF-MSCs (p<0,05).
Conclusion: Our results support immunoregulatory effects of DF-MSCs on both AD and psoriasis which are Th2 and Th1 / Th17 dominant diseases respectively. Our evidence-based results demonstrated that DF-MSCs could have a beneficial therapeutic implication for inflammatory skin diseases.
Anahtar Kelimeler
Mesenchymal Stem Cells Immunoregulation Soluble factors Atopic Dermatitis Psoriasis
Kaynakça
- 1. Drucker AM. Atopic dermatitis: burden of illness, quality of life, and associated complications. Allergy Asthma Proc 2017; 38: 3–8.
- 2. Bieber T. Atopic dermatitis. Ann Dermatol 2010; 22: 125–137.
- 3. Brunner PM, Guttman-Yassky E, Leung DY. The immunology of atopic dermatitis and its reversibility with broad-spectrum and targeted therapies. J Allergy Clin Immunol 2017; 139: 65–76.
- 4. Nutten S. Atopic dermatitis: Global epidemiology and risk factors. Ann Nutr Metab 2015; 66: 8–16.
- 5. Shaw TE, Currie GP, Koudelka CW, Simpson EL. Eczema prevalence in the United States: Data from the 2003 National Survey of Children’s Health. J Invest Dermatol 2011; 131: 67–73.
- 6. Leung DY, Nicklas RA, Li JT, Bernstein IL, Blessing- Moore J, Boguniewicz M va et al. Disease management of atopic dermatitis: an updated practice parameter. Joint Task Force on Practice Parameters. Ann Allergy Asthma Immunol 2004; 93: 1-21.
- 7. Bieber T. Atopic dermatitis. N Engl J Med 2008; 358:1483-1494.
- 8. Brunner PM, Leung DYM, Guttman-Yassky E. Immunologic, microbial, and epithelial interactions in atopic dermatitis. Ann Allergy Asthma Immunol 2018; 120: 34-41.
- 9. Lowes MA, Bowcock AM, Krueger JG. Pathogenesis and therapy of psoriasis. Nature 2007; 445: 66–73.
- 10. Guttman-Yassky E, Lowes MA, Fuentes-Duculan J, et al. Major differences in inflammatory dendritic cells and their products distinguish atopic dermatitis from psoriasis. J Allergy Clin Immunol 2007; 119: 1210–7.
- 11. Org PY, Leung DY. Immune dysregulation in atopic dermatitis. Curr Allergy Asthma Rep 2006; 6: 384–9.
- 12. Khattri S, Shemer A, Rozenblit M, Dhingra N, Czarnowicki T, Finney R va et al. Cyclosporine in patients with atopic dermatitis modulates activated inflammatory pathways and reverses epidermal pathology. J Allergy Clin Immunol 2014; 133: 1626-34.
- 13. Gooderham M, Lynde CW, Papp K, Bourcier M, Guenther L, Gulliver W va et al. Review of systemic treatment options for adult atopic dermatitis. J Cutan Med Surg 2016: 21:31-39.
- 14. Khattri S, Shemer A, Rozenblit M, Dhingra N, Czarnowicki T, Finney R, et al. biomarkers for therapeutic response. J Allergy Clin Immunol 2011; 128: 583-93.
- 15. Tintle S, Shemer A, Suarez-Farinas M, Fujita H, Gilleaudeau P, Sullivan-Whalen M va et al. Reversal of atopic dermatitis with narrow-band UVB phototherapy and biomarkers for therapeutic response. J Allergy Clin Immunol 2011; 128: 583-93.
- 16. Kim HS, Yun JW, Shin TH, Lee SH, Lee BC, Yu KR va et el. Human umbilical cord blood mesenchymal stem cell-derived PGE2 and TGF-beta1 alleviate atopic dermatitis by reducing mast cell degranulation. Stem cells 2015; 33:1254–66.
- 17. Na K, Yoo HS, Zhang YX, Choi MS, Lee K, Yi TG va et el. Bone marrow-derived clonal mesenchymal stem cells inhibit ovalbumin-induced atopic dermatitis. Cell Death Dis 2014; 5: e1345.
- 18. Barry FP, Murphy JM. Mesenchymal stem cells: clinical applications and biological characterization. Int J Biochem Cell Biol 2004; 36: 568–84.
- 19. Duffy MM, Ritter T, Ceredig R, Griffin MD. Mesenchymal stem cell effects on T-cell effector pathways. Stem Cell Res Ther 2011; 2: 34. 20. Saito M. T, Silverio K. G, Casati M. Z, SallumE. A, Nociti F. H. Jr Tooth-derived stem cells: Update and perspectives. World J Stem Cells 2015; 7: 399–407.
- 21. Yildirim S, Zibandeh N, Genc D, Ozcan EM, Goker K, Akkoc T. The Comparison of the Immunologic Properties of Stem Cells Isolated from Human Exfoliated Deciduous Teeth, Dental Pulp, and Dental Follicles. Stem Cells Int 2016; 4682875: 105-106.
- 22. Krampera M, Cosmi L, Angeli R, Pasini A, Liotta F, Andreini A va et al. Role for interferon-gamma in the immunomodulatory activity of human bone marrow mesenchymal stem cells. Stem Cells 2006; 24: 386–398. 23. Ryan JM, Barry F, Murphy JM, Mahon BP. Interferon-gamma does not break, but promotes the immunosuppressive capacity of adult human mesenchymal stem cells. Clin Exp Immunol 2007; 149: 353–63.
- 24. DelaRosa O, Lombardo E, Beraza A, Mancheno-Corvo P, Ramirez C, Menta R va et al. Requirement of IFN-gamma-mediated indoleamine 2,3-dioxygenase expression in the modulation of lymphocyte proliferation by human adipose-derived stem cells. Tissue Eng Part A 2009; 15: 2795–2806.
- 25. Fu Q, Chow Y, Sun S, Zeng Q, Li H, Shi J, et al. Mesenchymal stem cells derived from human induced pluripotent cells modulate T- cell phenotypes in allergic Rhinitis. Allergy 2012; 67: 1215-22.
- 26. Fuss IJ, Kanof M, Smith P, Zola H. Isolation of whole mononuclear cells from peripheral blood and cord blood. Curr Protoc Immunol 2009; Chapter 7:Unit7.1.
- 27. Quah B, Parish C. The Use of Carboxyfluorescein Diacetate Succinimidyl Ester (CFSE) to Monitor Lymphocyte Proliferation. J Vis Exp 2010; 4: 2259.
- 28. Massimiliano D’Erme A, Romanelli M, Chiricozzi A. Spotlight on dupilumab in the treatment of atopic dermatitis: design, development, and potential place in therapy. Drug Des Devel Ther 2017; 11: 1473–80.
- 29. Iyer SS , Rojas M. Anti-inflammatory effects of mesenchymal stem cells: novel concept for future therapies. Expert Opin Biol Ther. 2008; 8: 569-81.
- 30. Lee YS, Sah SK, Lee JH, Seo KW, Kang KS, Kim TY. Human umbilical cord blood-derived mesenchymal stem cells ameliorate psoriasis-like skin inflammation in mice. Biochem Biophys Rep 2016; 9: 281-8. 31. TW, Lim JH, Chung CJ, Kang TJ, Kim TY, Kim YS, et al. Immune Tolerance of Human Dental Pulp-Derived Mesenchymal Stem Cells Mediated by CD4+CD25+FoxP3+ Regulatory T-Cells and Induced by TGF-β1 and IL-10. Yonsei Med J 2017; 58: 1031–39.
- 32. Keyser KA, Beagles KE, Kiem HP. Comparison of mesenchymal stem cells from different tissues to suppress T-cell activation. Cell Transplant 2007; 16: 555-62.
Toplam 29 adet kaynakça vardır.
Ayrıntılar
| Birincil Dil | İngilizce |
|---|---|
| Konular | Sağlık Kurumları Yönetimi |
| Bölüm | Articles |
| Yazarlar | |
| Yayımlanma Tarihi | 30 Eylül 2019 |
| Gönderilme Tarihi | 11 Nisan 2018 |
| Yayımlandığı Sayı | Yıl 2019 Cilt: 9 Sayı: 3 |
Kaynak Göster
Cited By
Therapeutic Functions of Stem Cells from Oral Cavity: An Update
International Journal of Molecular Sciences
https://doi.org/10.3390/ijms21124389
